RxDoctor Payments Data

J Kellman, DO

Family Medicine · Livonia, MINPI 1386624187

Payments from drug & device makers

$11,349in general payments, 2019–2025

Across 732 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$835
  • AbbVie$730
  • Pfizer$532
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,349 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$157,078
Medicare patients
234
Services billed
5,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$164,853
JardianceEmpagliflozin125$126,126
TradjentaLinagliptin49$54,298
EliquisApixaban53$51,344
FarxigaDapagliflozin Propanediol49$51,052
MounjaroTirzepatide23$35,412
XareltoRivaroxaban25$28,197
Tresiba Flextouch U-200Insulin Degludec11$22,796
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$21,672
JanuviaSitagliptin Phosphate18$21,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,790
RexultiBrexpiprazole12$16,265
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$11,803
MyrbetriqMirabegron12$11,602
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$10,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$835$180,423174 claims
Novo NordiskOzempic$2,168$164,853134 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,039$58,32860 claims
PfizerEliquis$532$51,34453 claims
Lilly USA, LLCMounjaro, Humalog$1,266$36,65034 claims
Johnson & JohnsonXarelto$455$28,19725 claims
GSKTrelegy Ellipta, Breo Ellipta$415$27,37637 claims
MerckJanuvia$405$21,63918 claims
Otsuka America Pharmaceutical, Inc.Rexulti$269$16,26512 claims
Astellas Pharma US IncMyrbetriq$145$11,60212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →